Uncategorized
Wedbush Analyst Remains Bullish on Apple (AAPL) Stock, While Others Bear Off
Shares of Apple (AAPL) have been down about 20% since its earnings report in early November and investors are becoming more bearish by …
How Does This Analyst Think Broadcom (AVGO) Is Going to Fight Off the Competition?
Broadcom (AVGO) has a new – or should we say more recent competitor – Amazon. Though the market just got a bit more …
Stemline Therapeutics (STML) Gets One Step Closer to EMA Approval; Analyst Weighs in With U.S. Angle
Stemline Therapeutics (STML) announced the European Medicines Agency (EMA) is granting accelerated assessment for the company’s marketing authorization for oral treatment, Elzonris. The …
Cowen Analyst Bullish On Vertex (VRTX) Stock After Company Releases Favorable Data
Biopharmaceutical Vertex’ (VRTX) is working on a trial called Phase III VX-659 and Cowen analyst Phil Nadeau calls some recently released data “Good …
What Does This Analyst Predict Will Happen With Apple (AAPL) Stock After Trump’s Tariff News?
It’s risky business. In an interview with the Wall Street Journal, President Trump suggests he may introduce a 10% tariff for Apple (AAPL) …
Analyst Holds His Breath After Trump Announces Possible Tariff for iPhones and Laptops
Wedbush’s Daniel Ives is hoping it’s all smoke and no fire. President Trump discussed with the Wall Street Journal the possibility of putting …
How Can Tesla (TSLA) Improve Sales for Q4 After Major Customer Dissatisfaction?
Tesla (TSLA) is rolling into winter hoping to finish the year on a high note, but the electric car company is hitting some …
Analyst Urges Investors to Buy NVIDIA (NVDA) Stock on Weakness — Before New Products Get Big Return
NVIDIA (NVDA) stock is inching its way back up the market after having a major fall over the course of the autumn season. At …
Why Does this Analyst Slash His Price Target in Half — Right Before Launch of Paratek Pharmaceuticals’ (PRTK) Drug NUZYRA?
Paratek Pharmaceuticals (PRTK) is preparing to launch its drug NUZYRA, following FDA approval granted on October 2nd. The medication treats both community-acquired bacterial …